Navigation Links
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
Date:8/7/2008

ion, the company no longer plans to conduct a longer-term Phase 2 study in patients switching from ERT to Plicera as previously disclosed. The design of the pharmacokinetics study is currently under development.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. In the second quarter of 2008, Amicus announced that it had initiated a Phase 2 clinical trial of AT2220 (1-deoxynojirimycin HCl). Amicus is conducting the study in adult Pompe patients in clinical centers throughout North America and Europe. AT2220 is the third compound based on Amicus' pharmacological chaperone technology platform to enter Phase 2 clinical development.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on these results, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus is accelerating its investment in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease, funded in part by a grant from the Michael J. Fox Foundation. In addition to the work in Parkinson's, Amicus is investing in new research aimed at evaluating disease targets for other neurodegenerative disorders and metabolic disorders.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration, valued at up to $440 million includi
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
3. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
9. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
10. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
11. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Diseases largely eradicated in the ... Measles was declared eliminated in 2000, yet the CDC ... 15—the highest incidence in 20 years. In July, ... cough a problem of "epidemic proportions." ... from these preventable diseases—in part because some parents (more ...
(Date:8/29/2014)... -- In part four of a blog series ... a strategic asset, Mary Baxter, MBA, RPh ., ... Innovation Delivery Solutions business, discusses how expanding patient access ... patients. "Every hospital pharmacist knows that filling ... in a value-based healthcare world," Baxter says. "For the ...
(Date:8/29/2014)... , August 29, 2014 ... and collaboration software has announced a major new deal ... founded by renowned pathology expert, Dr. Marius Nap ... of the 26th European Congress of Pathology which is ... the ExCeL Arena, London where ...
Breaking Medicine Technology:Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... N.J., April 3, 2012  Savient Pharmaceuticals, Inc. (NASDAQ: ... Vice President and President North American Commercial Operations, will ... Tuesday, April 17th, 2012 at 11:30 AM Eastern Time.  ... Palace Hotel, New York, NY. A live ...
...  AVT, Inc., (Ticker: AVTC) ( www.autoretail.com ), is a ... designed for use in hospitals, pharmacies, medical offices and ... to reduce and even eliminate prescription medicine dispensing errors. ... Journal of Pharmacy Practice reviewed 60 research papers that ...
Cached Medicine Technology:Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum 2Automated Medicine Dispensing Units Developed by AVT Can Reduce Errors 2
(Date:8/30/2014)... Albany, New York (PRWEB) August 30, 2014 ... a combination of Nutrition and Pharameuticals. Nutraceuticals is ... by extracting healthy ingredients from natural food sources. ... specific health benefits to the human body. Nutraceutical ... multivitamins, diet supplements, fortified foods and more. Although ...
(Date:8/30/2014)... August 30, 2014 The establishment ... planet has been one of the main strategies ... create a positive impact around the world. , ... with top trained executives and trainers deliver L. ... worldwide. Vital statistics demonstrate that significant reduction ...
(Date:8/30/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Cell Disruptor including its ... explores global and China’s top manufacturers of Cell ... and market share etc. The report further analyzes ...
(Date:8/30/2014)... Manhattan Beach, Calif. (PRWEB) August 30, 2014 ... Carol Francis helps listeners understand how they unknowingly developed insomnia ... and have restful nights during. Tune in to the ... . The show airs live on August 30, and ... For more information on programming, go to DrCarolFrancisTalkRadio.com. ...
(Date:8/30/2014)... August 30, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
Breaking Medicine News(10 mins):Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Executive Officer, Effective January 1, ... ... today announced a leadership transition plan under which Michael P.,Kaminski, currently President ... title and responsibilities of Chief Executive,Officer, effective January 1, 2009. At that ...
... According to the American Diabetes,Association, 23.6 million Americans ... of the groups hardest hit by this disease, ... Diabetes Month,Black Expressions(R) Book Club has put together ... offer information about prevention, nutrition,and diet tips., ...
... Average psychiatrist salary increased for 60 percent of survey respondents. ... ... research by physician recruiting firm LocumTenens.com indicates that among the medical ... least to lose if universal healthcare coverage is implemented under the ...
... rehab facility located in Malibu, recently celebrated its fourth anniversary with ... a party for current and past residents. , ... ... rehab facility located in Malibu, recently celebrated its fourth anniversary with ...
... study finds that recent progress in closing the gap ... may be due primarily to smoking-related cancers, and that ... still be increasing. The study, appearing in the November ... is the first to analyze racial and ethnic differences ...
... Percent Increase in IVUS System Sales, SAN DIEGO, ... a leader in the development, manufacturing and sales of,products ... artery,disease, today reported that revenues for the third quarter ... quarter of 2007., For the quarter ended September ...
Cached Medicine News:Health News:Stereotaxis Announces New Management Appointment 2Health News:Stereotaxis Announces New Management Appointment 3Health News:National Diabetes Month Book Suggestions From Black Expressions(R) Book Club 2Health News:LocumTenens.com Finds Psychiatrists are Neutral on Universal Healthcare 2Health News:LocumTenens.com Finds Psychiatrists are Neutral on Universal Healthcare 3Health News:Malibu Alcohol and Drug Rehab Center Celebrates Fourth Anniversary 2Health News:Study finds racial disparities increasing for cancers unrelated to smoking 2Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 2Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 3Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 4Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 5Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 6Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 7Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 8Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 9Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 10Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 11Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 12Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 13Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 14
World's first commercially available vacuum assisted biopsy device for MRI....
... Now you can perform stereotactic, ultrasound and ... convenience of your office. Use the patented, ... easier and more clinically advanced method of ... best for the women who trust YOU.,12 ...
... perform stereotactic, ultrasound and MRI-guided vacuum assisted ... office. Use the patented, FDA-cleared ATEC system ... clinically advanced method of breast biopsy. Its ... women who trust YOU.,9 Gauge Handpieces: Useful ...
36" Penrose drains...
Medicine Products: